SABCS 2023 | Novel non-coding CDH1 genetic alterations & fusion genes: how could they influence treatment of ILC?

Fresia Pareja, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on how the identification of novel non-coding CDH1 genetic alterations and fusion genes could help inform treatment strategies and the diagnosis of patients with invasive lobular carcinoma. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.